Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease. METHODS: We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease. RESULTS: We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects > or =65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700,000 subjects taking simvastatin and over 50,000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p < 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p < 0.0001). CONCLUSION: Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 6×
“We examined the number of hospitalizations and the Charlson Index during the study period, which is an index providing a general assessment of chronic disease [22].”
InfluentialShepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Statins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Wolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
Self-citationThe age-dependent relation of blood pressure to cognitive function and dementia
Qiu, C., Winblad, B., & Fratiglioni, L. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70141-1 · Cited by 1,138
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · cited 1×
“Some studies suggest that medications used to treat these risk factors are also associated with a reduced incidence of dementia [5-10].”
Aggregation of vascular risk factors and risk of incident Alzheimer disease
Luchsinger, J. A., Reitz, C., Honig, L. S., Tang, M. X., Shea, S., & Mayeux, R. (2005) · Neurology · doi:10.1212/01.wnl.0000172914.08967.dc · Cited by 790
Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam study
Breteler, M. M. B., Claus, J. J., Grobbee, D. E., & Hofman, A. (1994) · BMJ · doi:10.1136/bmj.308.6944.1604 · Cited by 541
Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., Wolfson, C., & McDowell, I. (2002) · Archives of Neurology · doi:10.1001/archneur.59.2.223 · Cited by 516
Newman, A. B., Fitzpatrick, A. L., Lopez, O., Jackson, S., Lyketsos, C., Jagust, W., Ives, D., DeKosky, S. T., & Kuller, L. H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53360.x · Cited by 492
Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
Yaffe, K., Barrett-Connor, E., Lin, F., & Grady, D. (2002) · Archives of Neurology · doi:10.1001/archneur.59.3.378 · Cited by 439
HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly Patients
Wang, P. S. (2000) · JAMA · doi:10.1001/jama.283.24.3211 · Cited by 416
Simons, M., Schwärzler, F., Lütjohann, D., Von Bergmann, K., Beyreuther, K., Dichgans, J., Wormstall, H., Hartmann, T., & Schulz, J. B. (2002) · Annals of Neurology · doi:10.1002/ana.10292 · Cited by 415
Kinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Leslie, S. J., Sasiela, W. J., Szarek, M., Libby, P., & Ganz, P. (2003) · Circulation · doi:10.1161/01.cir.0000091404.09558.af · Cited by 405
Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease: Preliminary Results
Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., Wasser, D., Johnson-Traver, S., Lochhead, J., & Ziolwolski, C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.5.753 · Cited by 319
Zandi, P. P. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.217 · Cited by 310
Statin Use and the Risk of Incident Dementia: The Cardiovascular Health Study
Rea, T. D., Breitner, J. C., Psaty, B. M., Fitzpatrick, A. L., Lopez, O. L., Newman, A. B., Hazzard, W. R., Zandi, P. P., Burke, G. L., Lyketsos, C. G., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1047 · Cited by 277
Saheki, A., Terasaki, T., Tamai, I., & Tsuji, A. (1994) · Pharmaceutical Research · doi:10.1023/a:1018975928974 · Cited by 206
SKOOG, I., LITHELL, H., HANSSON, L., ELMFELDT, D., HOFMAN, A., OLOFSSON, B., TRENKWALDER, P., & ZANCHETTI, A. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.02.013 · Cited by 199
Statin Safety and Drug Interactions: Clinical Implications
Bottorff, M. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.007 · Cited by 188
Statins: Effective antiatherosclerotic therapy
Blumenthal, R. S. (2000) · American Heart Journal · doi:10.1016/s0002-8703(00)90033-4 · Cited by 169
Implications of Cytochrome P450 Interactions When Prescribing Medication for Hypertension
Flockhart, D. A., & Tanus-Santos, J. E. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.4.405 · Cited by 150
Zhou, Z., Rahme, E., & Pilote, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.003 · Cited by 121
Cholesterol and Alzheimer's disease—is there a relation?
Sjögren, M. J. C., Mielke, M. M., Gustafson, D., Zandi, P. P., & Skoog, I. G. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.020 · Cited by 115
Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs
Sohn, M.-W., Zhang, H., Arnold, N., Stroupe, K., Taylor, B. C., Wilt, T. J., & Hynes, D. M. (2006) · Population Health Metrics · doi:10.1186/1478-7954-4-7 · Cited by 101
Cardiovascular Disease Risk Factors and Cognitive Impairment
Nash, D. T., & Fillit, H. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.031 · Cited by 100
Pharmacy Data in the VA Health Care System
Smith, M. W., & Joseph, G. J. (2003) · Medical Care Research and Review · doi:10.1177/1077558703256726 · Cited by 87
Re-assessing the relationship between cholesterol, statins and Alzheimer's disease
Wolozin, B., Manger, J., Bryant, R., Cordy, J., Green, R. C., & McKee, A. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00687.x · Cited by 84
Self-citationStatin Use and Fracture Risk: Study of a US Veterans Population
Scranton, R. E., Young, M., Lawler, E. V., Solomon, D. H., GAGNON, D. R., & Gaziano, J. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.17.2007 · Cited by 82
Prevalence of Dementia among Veterans Affairs Medical Care System Users
Krishnan, L. L., Petersen, N. J., Snow, A. L., Cully, J. A., Schulz, P. E., Graham, D. P., Morgan, R. O., Braun, U., Moffett, M. L., Yu, H.-J., et al. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000087345 · Cited by 80
Sironi, L., Gianazza, E., Gelosa, P., Guerrini, U., Nobili, E., Gianella, A., Cremonesi, B., Paoletti, R., & Tremoli, E. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000157145.98200.55 · Cited by 77
Karalis, D. G., Ross, A. M., Vacari, R. M., Zarren, H. S., & Scott, R. C. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02337-2 · Cited by 72
Statins of Different Brain Penetrability Differentially Affect CSF PLTP Activity
Vuletic, S., Riekse, R. G., Marcovina, S. M., Peskind, E. R., Hazzard, W. R., & Albers, J. J. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000095679 · Cited by 66
HMG-CoA Reductase Inhibition: Anti-Inflammatory Effects beyond Lipid Lowering?
März, W., & Köenig, W. (2003) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000073686.78271.6d · Cited by 64
Gresser, U., & Gathof, B. S. (2004) · PubMed · Cited by 52
Hunninghake, D. B., Ballantyne, C. M., Maccubbin, D., Shah, A. K., Gumbiner, B., & Mitchel, Y. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80162-5 · Cited by 44
Davidson, M. H. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.006 · Cited by 35
Chan, P., Huang, T., Tomlinson, B., Lee, C., & Lee, Y. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04327.x · Cited by 12
Combined antihypertensive and lipid-lowering treatment
Cesari, M., & Pessina, A. C. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0025-5 · Cited by 8
Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3 · cited 1×
“Some studies suggest that medications used to treat these risk factors are also associated with a reduced incidence of dementia [5-10].”
Cited by
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Linking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972
Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference
Cheng, F., Liu, C., Jiang, J., Lu, W., Li, W., Liu, G., Zhou, W., Huang, J., & Tang, Y. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002503 · Cited by 818
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Metadata
- Authors
- Wolozin, B., Wang, S. W., Li, N.-C., Lee, A., Lee, T. A., & Kazis, L. E.
- Venue
- BMC Medicine
- Published
- 2007-07-19
- Volume
- 5
- Issue
- 1
- Pages
- 20-20
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2105632027
- Cited by
- 383
- References
- 42
- FWCI
- 26.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.